DocGo Inc. Common Stock Earnings Recaps
DocGo shares declined 0.8% after reporting moderate revenue growth but margin pressures and ongoing losses tempered investor enthusiasm. Despite increasing revenue guidance, investors appeared cautious given continued adjusted EBITDA losses and headwinds from labor costs and rising fuel prices.
Key takeaways
- Q1 revenue totaled $75.6 million, driven by growth in virtual care and mobile phlebotomy segments.
- SteadyMD revenue exceeded $9 million with 38% year-over-year visit growth; workforce expanded 45% to address demand.
- Mobile phlebotomy revenue poised for up to 75% growth in 2026, with geographical expansion and technology integration planned.
- Adjusted EBITDA loss was $10.2 million; labor inefficiencies at SteadyMD and higher fuel costs compressed gross margins by approximately 95 basis points combined.
- Revenue guidance raised to $300–315 million for 2026, but adjusted EBITDA guidance maintained at a loss of $5–10 million, signaling cautious outlook on profitability.
DocGo's Q3 2025 results reflect strong operational momentum with record volumes across key business segments, underpinned by a robust balance sheet and strategic acquisition plans. The company anticipates significant growth in 2026, projecting revenues of $280 million to $300 million.
Key takeaways
- Achieved record volumes in medical transportation, driven by long-term contracts, with expectations to surpass $200 million in revenue for 2025.
- Announced acquisition of SteadyMD, expected to enhance growth in virtual care services and contribute $5 million to revenue in 2025.
- 2026 revenue guidance suggests 12%-20% growth year-over-year, with a path to adjusted EBITDA positive run rate by year-end.
- Targeted hiring initiatives in the EMS sector aim to capture additional revenue and improve service capacity.
- Multiple service lines are contributing positively to adjusted EBITDA, highlighting operational efficiency despite corporate overhead costs.
DocGo delivered strong performance in Q2 2025, highlighted by a substantial cash flow increase and strategic cost reductions, positioning the company for growth amid increasing demand for proactive healthcare solutions.
Key takeaways
- Cash flow from operations exceeded $30 million, contributing to a total cash balance of $128.7 million at quarter-end.
- Implementation of substantial SG&A reductions is projected to generate $10 million in annualized savings.
- Operational metrics met targets with over 176,000 medical transports and significant progress in care gap closure programs.
- Customer engagement has surged, with over 1.2 million assigned lives served, and a 50% increase in patient conversions compared to the prior quarter.
- Ongoing expansion efforts with significant contracts in new markets position DocGo for robust growth through 2026.